H.C. Wainwright raised the firm’s price target on MoonLake Immunotherapeutics to $75 from $37 and keeps a Buy rating on the shares. The analyst considers the company’s Phase 2 MIRA results to be the best data in hidradenitis suppurativa. The firm believes sonelokimab has a best-in-class profile and increased its probability of approval to 70%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See the top stocks recommended by analysts >>
Read More on MLTX: